Cadrenal Therapeutics (NASDAQ:CVKD) vs. Biodexa Pharmaceuticals (NASDAQ:BDRX) Financial Comparison

Cadrenal Therapeutics (NASDAQ:CVKD) and Biodexa Pharmaceuticals (NASDAQ:BDRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, analyst recommendations and earnings.

Analyst Ratings

This is a summary of recent ratings and price targets for Cadrenal Therapeutics and Biodexa Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cadrenal Therapeutics	1	0	1	0	2.00
Biodexa Pharmaceuticals	1	0	0	0	1.00

Cadrenal Therapeutics presently has a consensus target price of $32.00, suggesting a potential upside of 341.99%. Given Cadrenal Therapeutics’ stronger consensus rating and higher possible upside, equities analysts clearly believe Cadrenal Therapeutics is more favorable than Biodexa Pharmaceuticals.

Volatility and Risk

Cadrenal Therapeutics has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. Comparatively, Biodexa Pharmaceuticals has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500.

Insider & Institutional Ownership

7.9% of Cadrenal Therapeutics shares are owned by institutional investors. Comparatively, 17.5% of Biodexa Pharmaceuticals shares are owned by institutional investors. 26.1% of Cadrenal Therapeutics shares are owned by company insiders. Comparatively, 0.3% of Biodexa Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Cadrenal Therapeutics and Biodexa Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cadrenal Therapeutics	N/A	-279.50%	-204.46%
Biodexa Pharmaceuticals	N/A	N/A	N/A

Earnings and Valuation

This table compares Cadrenal Therapeutics and Biodexa Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cadrenal Therapeutics	N/A	N/A	-$10.65 million	($8.01)	-0.90
Biodexa Pharmaceuticals	$470,000.00	4.26	-$7.32 million	N/A	N/A

Biodexa Pharmaceuticals has higher revenue and earnings than Cadrenal Therapeutics.

About Cadrenal Therapeutics

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

About Biodexa Pharmaceuticals

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.